The Busy Girl's Guide to Aesthetics
2020 has been full of surprises that no one was prepared for. Although the complicated situation brings to us a lot of unusual circumstances and obstacles, it reveals a brand new perspective to the Medical Aesthetic industry and reformulates the expectations of the business success during the ‘new normal’.
The Medical Aesthetic continues to grow and expand its’ outlook despite the social distancing which was required worldwide because of COVID – 19.
It’s been a year of cosmetic self-reflection focused on Instagram selfies, Youtube channels and spicy comments on social media, driven by controversies around buttock augmentation and with focus into the perfect glass-like looking skin.
2020 , also unveiled an array of new development in aesthetic devices.
Here; at the Busy Girl's Guide to Aesthetics, I have selected a few of the latest developments that have sought approval.
Cynosure Launches Elite iQ™
Cynosure announced the U.S., European and Australian launch of the Elite iQ™ platform, the next generation of the Elite+™ Aesthetic Workstation that allows for faster treatments with higher max energy compared to previous generation devices. The Elite iQ platform leverages Skintel®, the aesthetic industry’s only live Melanin Reader™, to offer customized laser hair removal treatments and permanently reduce unwanted hair for all skin types, anywhere on the body including the face, back, chest, arms, underarms, bikini area and legs.
Armed with patented Skintel technology, which measures melanin and reads specific skin types of patients allowing for real-time adjustment of treatments settings, the Elite iQ workstation solves the challenges historically encountered by practitioners when treating men and women with darker skin types.
The Elite iQ device meets the growing market demand for hair removal and skin revitalization solutions for men and women across all skin types. At Cynosure, the needs of our customers and their patients and this elevates our industry-leading technology with even greater power, efficiency and safety.
The Elite iQ device not only offers personalised hair removal treatments, but it also enables practitioners to perform the most requested aesthetic treatments to both revitalise and treat common skin concerns including unwanted hair, facial and leg veins, sun damage, facial wrinkles and razor bumps, all on a single device without surgery.
Intelligent Diode Laser Venus Epileve™
Venus Concept, a global medical aesthetic technology leader, announce that it has received a medical device license issued by Health Canada and CE Mark to market Venus Epileve. It is intended as a treatment of permanent hair reduction.
Venus Epileve represents a new product introduction that expands the Company’s diode laser hair removal offering beyond the Venus Velocity which was introduced to the medical aesthetics market in 2017.
The Venus Epileve is cost-effective, fast, comfortable, and can be used on all skin types (Fitzpatrick skin types I-VI), including tanned skin. The Venus Epileve is a portable and versatile tabletop device that offers two modes of operation (SLIDE and PULSE) and a real-time cooling system aimed at ensuring patient safety and comfort.
The Venus Epileve is integrated with Internet of Things (IoT) technology that collects technical information to help providers enhance business operations and improve treatment efficiency.
U.S. FDA Approves Qwo™, the First Injectable Treatment for Cellulite
Endo International plc announced that it received U.S. Food and Drug Administration (FDA) approval of Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women.
QWO is the first FDA-approved injectable treatment for cellulite. FDA approval of QWO is a key achievement in the continued execution of Endo’s long-term strategy, especially as it relates to building our portfolio and capabilities for the future. As Endo embarks on an exciting new journey into medical aesthetics, we look forward to bringing this innovative treatment to market through our Endo Aesthetics organisation.
While cellulite is known to be a multi-factorial condition, a primary contributing factor is the fibrous connective tissue, called the “fibrous septae.
These fibrous septae tether the skin, drawing it downward and leading to a mattress-like appearance, commonly referred to as “dimpling.”.
When injected into the treatment area, QWO is thought to release the fibrous septae enzymatically by specifically targeting Types 1 and 3 collagen, which may result in smoothing of the skin and an improved appearance of cellulite.
Restylane Kysse receives FDA approval
Galderma’s Restylane Kysse has been approved by the FDA for lip augmentation and the correction of upper perioral rhytids in adults aged 21 and above.
The hyaluronic acid filler contains 3mg/mL of lidocaine hydrochloride and is part of the Restylane range, which includes Restylane Classic, Lyft, Refyne, Fynesse, Volyme, Defyne; and skin boosters Vital and Vital Light.
The FDA approval was based on a randomised, controlled, evaluator-blinded, multicentre phase 3 study involving 273 patients.
Restylane Kysse is a new lip filler that offers key attributes both providers and their patients desire in a lip injection – high satisfaction, consistent results, and has a proven clinical-safety profile
Crown Aesthetics, SkinPen
The certification confirms SkinPen as a treatment to improve the appearance of facial acne scars in adults to improve the appearance of fine lines and wrinkles on the face and neck.
The British Standards Institution (BSI) granted a Class IIa CE Certification mark to Crown Aesthetics’ SkinPen Precision. The certification confirms, the SkinPen is also intended to treat pigmentation conditions including Melasma, Vitiligo and Solar Lentigines.
With SkinPen’s advanced microneedling technology, it continue to set a higher standard in patient care, and firmly establishes the industry benchmark for safety. This essential certification continues to offer the best in class technology to all clinicians and their patients and solidifies the company’s growing presence in the global market